The average mid cap score is 65.61, above the four week moving average score of 63.41. The average mid cap is trading -14.45% below its 52 week high, 2.57% above its 200 dma, has 6.98 days to cover held short, and is expected to post EPS growth of 17.1% next year.

ONTY and CLDX announced they have initiated a combined clinical trial of ONT-10 and varlilumab. NPSP announced the company has initiated a global registration study of teduglutide in pediatric patients.

The average mid cap score is 62.15, above the four week moving average score of 58.03. The average mid cap stock is trading -17.55% below its 52 week high, -1.76% below its 200 dma, has 6.96 days to cover held short, and is expected to grow EPS by 18.3% next year.

The average mid cap score is 52.91, below the four week moving average score of 55.99. The average mid cap stock is trading -21.73% below its 52 week high, -7.24% below its 200 dma, has 7.95 days to cover held short, and is expected to post EPS growth of 18.6% next year.

The average mid cap score across our universe is 58.37 this week, above the four week moving average score of 56.71.

NPS Pharmaceuticals (NPSP) received encouraging news when the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the FDA recommended the approval of the company’s hormone replacement therapy Natpara (rhPTH [1-84]).